{"symbol":"GILD","fiscalQuarter":"Q2-2026","reportDate":"2026-08-06","reportTime":"AMC","status":"upcoming","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q2-2026","preBrief":{"companySnapshot":"Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines in areas like HIV, liver diseases, and cancer. With a market cap of $171 billion, Gilead plays a significant role in the health care sector, particularly in addressing unmet medical needs.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"Expected to be around $2.03."},{"name":"Revenue Growth","why":"Revenue growth is crucial for assessing the company's ability to expand its market presence and support future innovations.","consensus":"Not available."},{"name":"Product Pipeline Updates","why":"Updates on new drugs and treatments in the pipeline can significantly impact investor sentiment and stock performance.","consensus":"Not available."}],"lastQuarterRecap":{"summary":"In Q1 2026, Gilead reported an EPS of $2.03, exceeding estimates by 7.69%. However, the stock experienced a slight decline of 1.64% the following day.","promises":["Continued investment in research and development.","Focus on expanding access to existing therapies.","Commitment to advancing their pipeline of new treatments."]},"wallStreetExpectations":{"summary":"Investors are cautiously optimistic about Gilead's upcoming earnings, particularly given its track record of beating EPS estimates. However, the lack of revenue guidance raises some uncertainty.","bullCase":"If Gilead continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.","bearCase":"Concerns about revenue growth and the effectiveness of its product pipeline could lead to disappointment, especially if the company fails to provide clear guidance."},"optionsSignal":{"impliedMove":"3.77%","context":"The options market is pricing in a move of about 3.77%, suggesting investors expect some volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+7.69%","reaction":"-1.64%"},{"quarter":"Q4-2025","epsSurprise":"+1.92%","reaction":"-2.93%"},{"quarter":"Q3-2025","epsSurprise":"+14.62%","reaction":"-0.05%"},{"quarter":"Q2-2025","epsSurprise":"+0.80%","reaction":"+0.00%"},{"quarter":"Q1-2025","epsSurprise":"+3.31%","reaction":"-0.22%"},{"quarter":"Q4-2024","epsSurprise":"+13.91%","reaction":"+0.69%"},{"quarter":"Q3-2024","epsSurprise":"+28.01%","reaction":"+1.63%"},{"quarter":"Q2-2024","epsSurprise":"+25.08%","reaction":"+2.15%"}],"pivotalQuestions":[{"question":"What is the expected revenue growth for the upcoming quarter?","whyItMatters":"Revenue growth is critical for assessing Gilead's market position and ability to sustain its operations and investments."},{"question":"What updates can management provide on the product pipeline?","whyItMatters":"Insights into the pipeline can significantly influence investor sentiment and expectations for future performance."}],"thesisBreakLevels":{"bullTrigger":"If Gilead reports an EPS above $2.03 and provides positive guidance on revenue growth.","bearTrigger":"If the EPS falls below $2.03 and there are no updates on the product pipeline.","context":"This quarter's performance will hinge on Gilead's ability to maintain its EPS growth while addressing concerns about revenue and product development."},"scenarioPlaybook":{"beatAndRaise":"If Gilead beats expectations, history suggests the stock could see an average one-day move of around -0.05%, confirming a strong operational outlook.","inLineCautious":"If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.","miss":"If Gilead misses expectations, history suggests the stock could decline, potentially reflecting investor disappointment."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"14 of 29 (48%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +3.2% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the potential for Gilead's product pipeline to deliver unexpected growth, especially in emerging markets.","supportingPoints":["Gilead has consistently beaten EPS estimates, indicating strong operational performance.","The options market is pricing a 3.77% move, which is higher than historical averages, suggesting potential for a surprise.","Management's commitment to R&D could lead to breakthroughs that the market is not fully accounting for."],"riskToConsensus":"If Gilead's revenue growth exceeds expectations, it could challenge the current cautious outlook."},"whatToListenFor":["Any specific revenue guidance for the upcoming quarter.","Updates on the status of new drugs in the pipeline.","Management's commentary on market conditions and competitive landscape.","Insights into international sales performance.","Discussion on strategic partnerships or collaborations."],"metaDescription":"Gilead Sciences (GILD) reports Q2 2026 earnings August 6. Investors are watching for revenue growth and pipeline updates."}}